CS432890A3 - Mixture containing alpha-interferon - Google Patents

Mixture containing alpha-interferon

Info

Publication number
CS432890A3
CS432890A3 CS904328A CS432890A CS432890A3 CS 432890 A3 CS432890 A3 CS 432890A3 CS 904328 A CS904328 A CS 904328A CS 432890 A CS432890 A CS 432890A CS 432890 A3 CS432890 A3 CS 432890A3
Authority
CS
Czechoslovakia
Prior art keywords
interferon
mixture containing
containing alpha
alpha
mixture
Prior art date
Application number
CS904328A
Other languages
Czech (cs)
Inventor
Alberto Ferro
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CS432890A3 publication Critical patent/CS432890A3/en
Publication of CZ277712B6 publication Critical patent/CZ277712B6/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CS904328A 1989-09-28 1990-09-06 Mixture containing alpha-interferon CZ277712B6 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH351489 1989-09-28

Publications (2)

Publication Number Publication Date
CS432890A3 true CS432890A3 (en) 1992-12-16
CZ277712B6 CZ277712B6 (en) 1993-03-17

Family

ID=4257630

Country Status (26)

Country Link
EP (1) EP0420049B1 (en)
JP (1) JPH03130232A (en)
KR (1) KR910005886A (en)
CN (1) CN1050503A (en)
AR (1) AR244551A1 (en)
AT (1) ATE92334T1 (en)
AU (1) AU636653B2 (en)
CA (1) CA2024046A1 (en)
CZ (1) CZ277712B6 (en)
DD (1) DD298054A5 (en)
DE (1) DE59002183D1 (en)
FI (1) FI904756A7 (en)
HU (1) HU205555B (en)
IE (1) IE903479A1 (en)
IL (1) IL95769A0 (en)
IS (1) IS3631A7 (en)
MC (1) MC2149A1 (en)
MX (1) MX22522A (en)
MY (1) MY106615A (en)
NO (1) NO904218L (en)
NZ (1) NZ235153A (en)
PH (1) PH27531A (en)
PT (1) PT95454A (en)
RU (1) RU2008017C1 (en)
YU (1) YU184090A (en)
ZA (1) ZA907579B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028020A1 (en) * 1993-05-18 1994-12-08 Bukh Meditec A/S A method for the preparation of interferons
AP1168A (en) * 1996-05-09 2003-06-30 Feronpatent Ltd Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets.
AU730020B2 (en) * 1997-05-09 2001-02-22 Feronpatent Limited Stabilisation of interferons in aqueous solution for manufacture of sublingually administered tablets
ID28470A (en) * 1998-03-26 2001-05-24 Schering Corp FORMULATIONS FOR PROTECTION OF GLYCOL-INTERFERON ALFA POLYETHYLENE CONJUGATION
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
CN1175901C (en) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 Stable water solution of interferon
ES2349472T3 (en) 2004-08-12 2011-01-03 Schering Corporation STABLE FORMULATION OF PEGILATED INTERFERON.
DE102004048379A1 (en) 2004-10-01 2006-04-13 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Spring element made of sputtered shape memory alloy
CU23432B6 (en) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech STABILIZED FORMULATIONS CONTAINING GAMMA AND ALFA INTERFERONS IN POTENTIAL PROPORTIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821691A (en) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd Method for purifying α- and β-interferon
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
EP0124018B1 (en) * 1983-04-28 1987-11-25 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
EP0133767B1 (en) * 1983-08-04 1991-04-03 The Green Cross Corporation Gamma interferon composition
IL78231A (en) * 1985-03-25 1990-07-26 Schering Corp Stable gamma-interferon formulation
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones

Also Published As

Publication number Publication date
NO904218L (en) 1991-04-02
FI904756A7 (en) 1991-03-29
IL95769A0 (en) 1991-06-30
ATE92334T1 (en) 1993-08-15
DE59002183D1 (en) 1993-09-09
AU636653B2 (en) 1993-05-06
AU6309890A (en) 1991-04-11
PT95454A (en) 1991-05-22
FI904756A0 (en) 1990-09-27
EP0420049B1 (en) 1993-08-04
EP0420049A1 (en) 1991-04-03
KR910005886A (en) 1991-04-27
MC2149A1 (en) 1992-03-10
CZ277712B6 (en) 1993-03-17
IE903479A1 (en) 1991-04-10
ZA907579B (en) 1991-06-26
CA2024046A1 (en) 1991-03-29
YU184090A (en) 1992-09-07
IS3631A7 (en) 1991-03-29
RU2008017C1 (en) 1994-02-28
MY106615A (en) 1995-06-30
JPH03130232A (en) 1991-06-04
HUT56284A (en) 1991-08-28
NO904218D0 (en) 1990-09-27
PH27531A (en) 1993-08-18
MX22522A (en) 1993-10-01
CN1050503A (en) 1991-04-10
AR244551A1 (en) 1993-11-30
HU906021D0 (en) 1991-03-28
NZ235153A (en) 1993-03-26
HU205555B (en) 1992-05-28
DD298054A5 (en) 1992-02-06

Similar Documents

Publication Publication Date Title
GB2209477B (en) Mixer
HU901311D0 (en) Daptomycine solvent mixture
CS432890A3 (en) Mixture containing alpha-interferon
EP0426974A3 (en) Composition containing acetaminophen
GB8715174D0 (en) Static mixer
EP0420634A3 (en) High level mixer
EP0403661A4 (en) Mixer
GB2210224B (en) Mixer
GB8820435D0 (en) Mixing unit
GB2217619B (en) Mixers
GB2229106B (en) Mixing apparatus
SU1486350A1 (en) Mixer
HUT58560A (en) Mixing apparatus
GB8814083D0 (en) Polysocyanate mixture
GB8904617D0 (en) Mixing apparatus
GB8719736D0 (en) Mixing unit
SU1592297A1 (en) Asphalt-concrete mix
HU896597D0 (en) Activated mixture
GB9015179D0 (en) Mixers
PL278128A2 (en) Mixer
ZA909045B (en) Mixer
GB8912602D0 (en) Mixing process
CA58564S (en) Mixer
KR900002380Y1 (en) Mixer
CS217188A3 (en) Adhesive mixture